vrdn-001
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Dec 3, 2021 (NCT05176639)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06384547 | Phase 3 | May 23, 2024 | Viridian Therapeutics |
| NCT06021054 | Phase 3 | Nov 14, 2023 | Viridian Therapeutics |
| NCT05176639 | Phase 2/Phase 3 (Phase 3) | Dec 3, 2021 | Viridian Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viridian Therapeutics | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1